FDX1 and nonpapillary renal cell carcinoma: Fourth, although we confirmed that elesclomol targeted FDX1 and inhibited cell viability of BLCA, ccRCC, and PCa cells, the precise regulatory mechanisms remain unclear and require further exploration.